FOXO3a Reverses the Cisplatin Resistance in Ovarian Cancer

Arch Med Res. 2018 Feb;49(2):84-88. doi: 10.1016/j.arcmed.2018.04.014. Epub 2018 Apr 30.

Abstract

Objective: Ovarian cancer is one of the most serious disease in female reproductive system. Platinum is the first-line drug for the treatment of ovarian cancer, while the resistance of platinum drug in clinical hindered the relief ovarian cancer. Our previous study found that decreased FOXO3a might be a poor prognosis in human ovarian cancer. In this research, we study whether FOXO3a was involved in the mechanism of platinum drug resistance.

Methods: The CCK-8 and FACS analysis were used to monitor the survival of ovarian cancer, and the FOXO3a expression was detected by western-blot.

Results: We found that FOXO3a expression upregulated significantly in A2780 compared with A2780/DDP cells with the treatment of platinum. Moreover, overexpression of FOXO3a in ovarian cancer inversed the platinum resistance in ovarian cancer.

Conclusion: These observations reminded that the role of FOXO3a might be one of the critical mechanisms in developing platinum drug resistance in ovarian cancer.

Keywords: FOXO3a; Ovarian cancer; Platinum drug resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Apoptosis / drug effects
  • Carcinoma, Ovarian Epithelial / drug therapy*
  • Cell Line, Tumor
  • Cisplatin / therapeutic use*
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Forkhead Box Protein O3 / genetics*
  • Humans
  • Ovarian Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • FOXO3 protein, human
  • Forkhead Box Protein O3
  • Cisplatin